New drug combo aims to shrink tumors before cancer surgery
NCT ID NCT05977907
Summary
This study is testing whether giving two immunotherapy drugs (pembrolizumab and IO102-103) before surgery is safe and effective for people with head and neck cancer that can be removed by surgery. Researchers will give the drugs to 30 participants and closely monitor side effects and any delays to surgery. The main goal is to see how much the treatment shrinks the tumor before it is surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern Memorial Hospital
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact
-
Providence Cancer Institute
NOT_YET_RECRUITINGPortland, Oregon, 97213, United States
Contact
-
Sibley Memorial Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact
-
Thomas Jefferson University Hospital
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Conditions
Explore the condition pages connected to this study.